drugset
drugset / Trial / NCT02675530

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCT02675530 ↗

Phase 1 Completed 33 enrolled Yale University AstraZeneca · collab
NaSingle-groupOpen-label

Summary

This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.

Timeline

Start
2007-12
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.29 mg/kg —

Indications

schizophrenia